Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 7/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4055615 | 0.88 | SMN1; SMN2 (0.56) | CASRSMN1; SMN2MEN1KMT2AMAOA | |
| SCHEMBL3959603 | 0.83 | CASR (0.75) | CASRMEN1KMT2AHTTHTR1A | |
| SCHEMBL79765 | 0.82 | SMN1; SMN2 (0.76) | CASRSMN1; SMN2MEN1KMT2AHTT | |
| SCHEMBL29560 | 0.82 | SMN1; SMN2 (0.76) | CASRSMN1; SMN2MEN1KMT2AHTT | |
| SCHEMBL774613 | 0.82 | SMN1; SMN2 (0.76) | CASRSMN1; SMN2MEN1KMT2AHTT | |
| SCHEMBL13077588 | 0.82 | CASR (0.64) | CASRSMN1; SMN2MEN1KMT2AHTT | |
| SCHEMBL8202163 | 0.82 | SMN1; SMN2 (0.66) | CASRSMN1; SMN2MEN1KMT2AHTT | |
| SCHEMBL2893627 | 0.81 | SMN1; SMN2 (0.60) | CASRSMN1; SMN2MEN1KMT2AMAOA | |
| SCHEMBL9153343 | 0.81 | MAOA (0.47) | MAOAMAOBCYP3A4CYP2D6 | |
| SCHEMBL11877401 | 0.81 | CASR (0.73) | CASRSMN1; SMN2MEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349831-B2 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | AMGEN INC. (US) | 2013-01-08 | — | — | US | claimed |
| US-20080221101-A1 | Calcium receptor modulating agents | AMGEN INC. (US) | 2008-09-11 | — | — | US | claimed |
| US-8349831-B2 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | AMGEN INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20080221101-A1 | Calcium receptor modulating agents | AMGEN INC. (US) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221101-A1 | Calcium receptor modulating agents | CASR, RYR1, RYR2 | CASR 1/4885SMN1; SMN2 2433/4885MEN1 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.